@genomeweb.bsky.social recently sat down with Foundation Medicine on the launch of our newest test, FoundationOne®MRD. Read more: spkl.io/633257D6Xb *FoundationOne MRD is performed by SAGA Diagnostics US, Inc. and has not been cleared or approved by the FDA

We look forward to attending #EHA2026 and connecting with the global hematology community. Heading to Stockholm? Visit us at booth G1.01 (Hall C) - reach out to our team to learn more: spkl.io/633257B0Ud

#Research demonstrated the clinical validation of ctDNA tumor fraction dynamics as a prognostic biomarker in patients with mTNBC receiving chemo with or without immunotherapy. Results also showcased the value of serial ctDNA monitoring in patients who are responding to treatment: spkl.io/633227B0Wo

#ASCO26 has come to an end and our team is looking back at our time in Chicago last weekend! Thank you to all who stopped by our booth and connected with our team. #WeAreFMI

Proud to introduce FoundationOne®MRD,* the first-of-its-kind molecular residual disease test to combine structural variants and digital PCR. *FoundationOne MRD is performed by SAGA Diagnostics US, Inc. and has not been cleared or approved by the FDA.

New companion diagnostic announcement - our tissue-based comprehensive genomic profiling (CGP) test has been FDA-approved to identify patients with hormone receptor-positive, HER2-negative #BreastCancer with a PIK3CA mutation for a targeted therapy combination.

Interested in how Foundation Medicine’s new molecular residual disease assay* can support your clinical trials? Register for our webinar: event.on24.com/wcc/r/536220... *FoundationOne®MRD is performed by SAGA Diagnostics US, Inc. and has not been cleared or approved by the FDA.

Companion Diagnostic Approval - our tissue and blood-based comprehensive genomic profiling (CGP) tests have been approved by the FDA as companion diagnostics for a combination therapy to identify patients w/ HRR gene-mutated mCRPC: bit.ly/4amufuW

#ASCO26 - Results reported from the experimental arm of the phase II COPE trial provide insights on the impact of serial ctDNA genomic profiling for treatment guidance and outcomes for patients with non-small cell lung cancer. Visit us at booth 19145: spkl.io/6332076bIO#ASCO26

Utilizing real-world genomic data, two new pieces of #research being presented at #ASCO26 explore the prevalence & co-occurrence patterns of HRDsig status in two disease areas: advanced breast cancer & advanced gallbladder adenocarcinoma. Meet w/ our team: spkl.io/6332876vwo

We're thrilled to announce the launch of our FoundationOne®MRD* tumor-informed molecular residual disease test. Read more: spkl.io/6332576Qhh *FoundationOne MRD is performed by SAGA Diagnostics US, Inc. and has not been cleared or approved by the FDA

Updates in #RareCancer research: New insights from the TRACK study found that comprehensive genomic profiling identified pathogenic alterations in nearly all rare cancer patients, w/ tissue-agnostic, actionable biomarkers seen in 9% of tumor types. Meet w/ us at #ASCO26, booth 19145: bit.ly/4af2Lau

#ResearchHighlights from Foundation Medicine at #ASCO26: copy number loss. Two studies will provide insights on common homozygous gene losses in head and neck cancer and the ability of liquid biopsy CGP to detect MTAP loss.

We are excited to launch advanced digital solutions for healthcare providers through an integration with navify® Clinical Hub, including AI-powered clinical trial matching, publication search, patient education materials and digitized guideline mapping.

A recent publication explored the key role of biomarker testing utilizing Foundation Medicine’s tissue-based comprehensive genomic profiling assay. Results showcase the importance of CGP testing to identify actionable biomarkers across all subtypes of non-small cell lung cancer.

New insights on copy number loss detection, circulating tumor DNA (ctDNA) genomic profiling, our proprietary homologous recombination deficiency signature (HRDsig) & more at #ASCO26. Explore our research being presented: www.foundationmedicine.com/press-releas...

Excited to announce that our tissue-based comprehensive genomic profiling (CGP) test has been approved by the FDA as a companion diagnostic for another targeted therapy to identify patients with MET Exon 14 skipping alterations in NSCLC: www.foundationmedicine.com/press-releas...

Our research published in Clinical Cancer Research introduces Foundation Medicine’s research use only AmpRatio biomarker, an NGS-based approach that precisely measures the magnitude of gene amplification by accounting for tumor ploidy. Scroll through to explore more insights.

We’re excited to join @statnews.com again this year at the STAT@ASCO: Science vs. Cancer event as the presenting sponsor, featuring a session with our CEO Dan Malarek. Going to be in Chicago? Join us: spkl.io/63324AhDbr

We are excited to provide a pharmacogenetic offering along w/ our portfolio of high-quality comprehensive genomic profiling tests. This new test can help healthcare providers gain a deeper understanding to help guide cancer therapy selection & support more effective patient care.

Foundation Medicine is heading to Chicago for #ASCO26! We’re excited to showcase our latest research, high-quality testing portfolio and our biopharma services and capabilities. Our team would love to meet with you, schedule time today: spkl.io/63322ACJXr

#DYK MTAP loss is a highly prevalent alteration actively being targeted in clinical trials, but its complexity can derail programs if not addressed early. Hear more about peer-reviewed data & see how biomarker decisions can impact clinical trials. Sign up: spkl.io/63329A784t

This month, we’re helping shine a light on the importance of #SkinCancer and #Melanoma awareness. By encouraging sun-safe habits and greater education, we can help spread more information about the signs and risks.

Through our partnership with Fulgent Genetics, our new offering helps identify genetic differences that can influence how medicines are metabolized and processed by the body, including genes such as DPYD. Explore more about our latest product: www.foundationmedicine.com/press-releas...

🧬 Today we recognize DNA Day and the impact of genomics in science, medicine and patient care. We are proud to play a role in all the progress happening today and look forward to continuing to help drive advancements in precision medicine.

#Research published in @natcomms.nature.com highlights the potential utility of circulating tumor DNA (ctDNA) monitoring for informing early treatment response in patients with advanced breast cancer.

Join us at #COA2026 in Orlando! Meet our team to learn how we support innovation in community oncology with high quality testing and genomic insights: spkl.io/63323A42DL

Our collaboration with Bristol Myers Squibb will develop a next-generation sequencing-based companion diagnostic to identify patients with homozygous MTAP deletion in multiple indications for an investigational targeted therapy. Learn more: www.foundationmedicine.com/press-releas...

#AACR26 - A new study utilized a tissue-informed molecular residual disease assay developed by Foundation Medicine. Findings showcased the potential utility of this assay in a pan-tumor & early cancer setting. Learn more about us – visit booth 2125: spkl.io/63323ANvUB

At #AACR26, we’re presenting new #research that assessed copy number loss prevalence in 400,000+ pan-tumor samples using Foundation Medicine’s tissue-based comprehensive genomic profiling. Hear more & connect with us, visit booth 2125: spkl.io/63321ANvmN

Foundation Medicine is heading to #AACR26! Excited to join the cancer research community for conversations on the latest innovations in precision medicine and cancer care. We hope to see you in San Diego! Explore more at the link here: spkl.io/63324A2jIm

We’re heading to San Juan for #SGOAM26! Connect with the Foundation Medicine team to learn more about our high-quality genomic tests and services for gynecologic cancers at booth 112. Explore more: spkl.io/63325AFeWL

In 2025, we demonstrated strong evidence that helped differentiate our portfolio of biomarker tests through the publication of over 200 pieces of research. Looking forward to the year ahead and showcasing where Foundation Medicine can make a difference in precision medicine.

We're proud to participate in the 16th World Clinical Biomarkers & Companion Diagnostics Summit Europe. Visit our booth to learn how our comprehensive genomic profiling & biomarker-driven solutions support biopharma partners from discovery through global commercialization.

Join us for an upcoming live webinar: How WGS is Changing Drug Development in Complex Diseases. Tune in to learn more about expanding precision strategies beyond oncology. Register here: spkl.io/63328ALkEs

We’re heading to San Antonio for #USCAP2026! Come learn more about Foundation Medicine and our high-quality tests and services at booth 443. Explore more: spkl.io/63328AIaPk

Now available through Foundation Medicine’s FlexOMx Lab™ - Whole Genome Sequencing Germline for research use. Drawing on our rich history of scientific firsts in precision oncology, we are applying that expertise to new disease areas.

Proud to support the National Cancer Institute & @eaonc.bsky.social ComboMATCH initiative. Now with the inclusion of our blood-based biomarker test, results will continue to help determine trial eligibility for patients who may benefit from the effectiveness of biomarker-targeted cancer treatment.

March is Colorectal Cancer Awareness Month. We are proud to support the colorectal cancer community in spreading greater awareness around prevention, early detection and access to resources for this disease.

Foundation Medicine is looking forward to engaging with the latest research in genitourinary (GU) cancers at #GU26. New #research from the team showcases new insights around MTAP loss in GU cancers. Stop by booth 8 to meet with us. Learn more: bit.ly/4qWCunb

We’re presenting several #ProstateCancer posters at #GU26 covering insights on HRDsig, TP53 mutations & the clinical validity of Foundation Medicine’s tissue-based companion diagnostic test to identify BRCA+ & other HRR+ patients w/ metastatic castration-sensitive prostate cancer

Miss. Not. One. at #GU26! Connect with our team at booth 8 & discover how advancements in comprehensive genomic profiling can help healthcare providers make confident, personalized treatment decisions for their patients with advanced cancer. Learn more: spkl.io/63323AQt6F

Deep dive into gene fusions and how testing for fusions with DNA and RNA is so important for their detection in our latest “Genomics in Moments” video. Watch below.

February is Gallbladder and Bile Duct Cancer Awareness Month. By supporting education around these rare cancers —and continuing to spread awareness—we can help encourage conversations, drive greater understanding and provide resources to those affected by these diseases.

New #research from our team explored the potential benefits of concurrent RNA-based next-generation sequencing (NGS) with DNA-based NGS to help improve genomic rearrangement detection. Learn more from the study published in The Oncologist: spkl.io/63320AsJVy

Foundation Medicine is heading to the 10th Annual Liquid Biopsy for Precision Oncology Summit! With a full schedule of events, including a plenary session, dinner program & booth exhibit, our team is looking forward to connecting on the latest innovations in liquid biopsy.

True or false: methyl thioadenosine phosphorylase (MTAP) loss is a rare alteration? Healthcare providers, if you’re not seeing MTAP loss in ~1 in 10 solid tumors, you may be missing out on clinical trial opportunities. Explore our abstract for more: spkl.io/63324AU56K

Explore a new review article published in spkl.io/63328AWm9w – “Circulating tumor DNA as a biomarker in early phase clinical trials.” Read more: spkl.io/63320AWm9j

"By integrating our high-quality genomic data with ConcertAl's electronic health data, we have created one of the most powerful new real-world data sets that enables insights to be turned into strategic decisions at critical milestones for our partners."

New #study at #GI26 utilizes genomic data from Foundation Medicine to explore the relationship between ERBB2 amplification and gene- and protein-level expression in GI cancers to understand combined predictive value.